Kiniksa Pharmaceuticals International, plc KNSA
Set alert
92.24 USD -5.32 -5.45%
At close · Oct 30
92.15 -0.09 -0.10%
After hours · Oct 30, 4:56 PM ET
91.25 Day range 98.48
37.01 52-week range 97.56
- YTD
- +123.61%
- 1 year
- +147.36%
- Open
- 97.60
- Prev close
- 97.56
- Mkt cap
- 7.25B
- Vol
- 1.32M
- Avg vol
- 620.55K
- EPS
- 1.32
- P/E
- 69.88
- Div yield
- 0.00%
More statistics
- Low
- 91.25
- High
- 98.48
- Forward P/E
- 42.80
- Beta
- 0.04
- Short ratio
- 6.53
- Inst. own
- 101.26%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 23, 2027
- 50-d avg
- 78.88
- 200-d avg
- 59.94
- 1y target
- 103.63
MAX chart
Events in this range
- Oct 28, 2025Earnings: 0.23; estimate 0.33; surprise -30.3%
- Feb 24, 2026Earnings: 0.17; estimate 0.29; surprise -41.38%
- Apr 28, 2026Earnings: 0.27; estimate 0.18; surprise 50%
- Jul 28, 2026Earnings: 0.3; estimate 0.2995; surprise 0.17%
- Jul 29, 2026Rating: Canaccord Genuity · Buy → Buy
- Jul 29, 2026Rating: JP Morgan · Overweight → Overweight
- Jul 30, 2026Rating: Goldman Sachs · Buy → Buy
- Oct 27, 2026Earnings: 0.56; estimate 0.371; surprise 50.94%
- Oct 28, 2026Rating: Wells Fargo · Overweight → Overweight
- Oct 28, 2026Rating: Wedbush · Outperform → Outperform
- Oct 28, 2026Rating: Goldman Sachs · Buy → Buy
Signals (141)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 26, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 26, 2026 | 6 days ago |
| RSI: Overbought | Oct 26, 2026 | 6 days ago |
| SMA: Bearish | Oct 19, 2026 | 1 week ago |
| SMA: Bullish | Oct 5, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 5, 2026 | 3 weeks ago |
| RSI: Overbought | Oct 5, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| RSI: Overbought | Jul 27, 2026 | 3 months ago |
| RSI: Overbought | Jun 29, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 8, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 1, 2026 | 5 months ago |
| SMA: Bearish | May 25, 2026 | 5 months ago |
| RSI: Overbought | May 4, 2026 | 6 months ago |
| SMA: Bullish | Apr 27, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 27, 2026 | 6 months ago |
| SMA: Bearish | Apr 13, 2026 | 6 months ago |
| MACD: Sell Signal | Feb 23, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 16, 2026 | 8 months ago |
| RSI: Overbought | Feb 16, 2026 | 8 months ago |
| SMA: Bullish | Jan 19, 2026 | 9 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 29, 2025 | 10 months ago |
| RSI: Overbought | Dec 15, 2025 | 10 months ago |
| RSI: Overbought | Nov 10, 2025 | 11 months ago |
| RSI: Overbought | Sep 29, 2025 | 1 year ago |
| RSI: Overbought | Sep 1, 2025 | 1 year ago |
| SMA: Bullish | Jul 28, 2025 | 1 year ago |
| SMA: Bearish | Jul 21, 2025 | 1 year ago |
| RSI: Overbought | Jun 2, 2025 | 1 year ago |
| SMA: Bullish | Apr 28, 2025 | 1 year ago |
| SMA: Bullish | Apr 21, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| SMA: Bullish | Mar 10, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 3, 2025 | 1 year ago |
| SMA: Bullish | Feb 17, 2025 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bearish | Oct 28, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 28, 2024 | 2 years ago |
| SMA: Bullish | Oct 7, 2024 | 2 years ago |
| SMA: Bearish | Sep 23, 2024 | 2 years ago |
| RSI: Overbought | Jul 22, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 8, 2024 | 2 years ago |
| SMA: Bullish | Jul 1, 2024 | 2 years ago |
| SMA: Bullish | Jul 1, 2024 | 2 years ago |
| SMA: Bearish | Jun 17, 2024 | 2 years ago |
| SMA: Bearish | Jun 10, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| SMA: Bearish | Apr 1, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 1, 2024 | 2 years ago |
| SMA: Bearish | Mar 25, 2024 | 2 years ago |
| RSI: Overbought | Feb 26, 2024 | 2 years ago |
| MACD: Buy Signal | Dec 11, 2023 | 2 years ago |
| SMA: Bullish | Nov 27, 2023 | 2 years ago |
| SMA: Bullish | Nov 13, 2023 | 2 years ago |
| SMA: Bearish | Nov 6, 2023 | 2 years ago |
| MACD: Sell Signal | Oct 2, 2023 | 3 years ago |
| SMA: Bearish | Sep 18, 2023 | 3 years ago |
| RSI: Overbought | Jul 24, 2023 | 3 years ago |
| SMA: Bullish | Jul 10, 2023 | 3 years ago |
| SMA: Bearish | Jul 3, 2023 | 3 years ago |
| SMA: Bullish | May 22, 2023 | 3 years ago |
| SMA: Bearish | May 15, 2023 | 3 years ago |
| MACD: Buy Signal | May 8, 2023 | 3 years ago |
| SMA: Bullish | May 1, 2023 | 3 years ago |
| SMA: Bullish | May 1, 2023 | 3 years ago |
| SMA: Bearish | Feb 20, 2023 | 3 years ago |
| SMA: Bearish | Jan 9, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 9, 2023 | 3 years ago |
| SMA: Bullish | Jan 2, 2023 | 3 years ago |
| SMA: Bearish | Dec 26, 2022 | 3 years ago |
| SMA: Bullish | Oct 31, 2022 | 4 years ago |
| SMA: Bearish | Oct 24, 2022 | 4 years ago |
| SMA: Bullish | Sep 26, 2022 | 4 years ago |
| SMA: Bearish | Aug 29, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bearish | Jul 25, 2022 | 4 years ago |
| SMA: Bullish | Jul 4, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 20, 2022 | 4 years ago |
| SMA: Bullish | Jun 13, 2022 | 4 years ago |
| MACD: Sell Signal | May 2, 2022 | 4 years ago |
| SMA: Bearish | Apr 18, 2022 | 4 years ago |
| SMA: Bullish | Mar 28, 2022 | 4 years ago |
| MACD: Buy Signal | Mar 28, 2022 | 4 years ago |
| SMA: Bearish | Mar 21, 2022 | 4 years ago |
| SMA: Bullish | Mar 14, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 17, 2022 | 4 years ago |
| SMA: Bearish | Dec 27, 2021 | 4 years ago |
| SMA: Bearish | Dec 27, 2021 | 4 years ago |
| SMA: Bullish | Dec 6, 2021 | 4 years ago |
| SMA: Bullish | Dec 6, 2021 | 4 years ago |
| SMA: Bearish | Nov 22, 2021 | 4 years ago |
| SMA: Bullish | Nov 1, 2021 | 5 years ago |
| SMA: Bullish | Nov 1, 2021 | 5 years ago |
| MACD: Buy Signal | Nov 1, 2021 | 5 years ago |
| SMA: Bearish | Aug 2, 2021 | 5 years ago |
| MACD: Sell Signal | Aug 2, 2021 | 5 years ago |
| MACD: Buy Signal | Jul 26, 2021 | 5 years ago |
| SMA: Bullish | Jul 19, 2021 | 5 years ago |
| SMA: Bearish | Jul 12, 2021 | 5 years ago |
| SMA: Bullish | Jul 5, 2021 | 5 years ago |
| SMA: Bearish | Jun 28, 2021 | 5 years ago |
| SMA: Bullish | Jun 14, 2021 | 5 years ago |
| SMA: Bearish | Mar 22, 2021 | 5 years ago |
| MACD: Sell Signal | Mar 22, 2021 | 5 years ago |
| SMA: Bearish | Mar 15, 2021 | 5 years ago |
| SMA: Bullish | Jan 4, 2021 | 5 years ago |
| SMA: Bearish | Dec 28, 2020 | 5 years ago |
| SMA: Bullish | Dec 14, 2020 | 5 years ago |
| MACD: Buy Signal | Dec 7, 2020 | 5 years ago |
| SMA: Bullish | Nov 23, 2020 | 5 years ago |
| SMA: Bearish | Oct 26, 2020 | 6 years ago |
| SMA: Bearish | Oct 12, 2020 | 6 years ago |
| SMA: Bullish | Oct 5, 2020 | 6 years ago |
| SMA: Bullish | Oct 5, 2020 | 6 years ago |
| SMA: Bearish | Aug 10, 2020 | 6 years ago |
| SMA: Bearish | Jul 20, 2020 | 6 years ago |
| MACD: Sell Signal | Jul 20, 2020 | 6 years ago |
| SMA: Bullish | Mar 30, 2020 | 6 years ago |
| MACD: Buy Signal | Mar 30, 2020 | 6 years ago |
| MACD: Sell Signal | Mar 23, 2020 | 6 years ago |
| SMA: Bearish | Mar 9, 2020 | 6 years ago |
| RSI: Overbought | Mar 2, 2020 | 6 years ago |
| RSI: Overbought | Feb 17, 2020 | 6 years ago |
| SMA: Bullish | Dec 9, 2019 | 6 years ago |
| SMA: Bullish | Nov 18, 2019 | 6 years ago |
| MACD: Buy Signal | Nov 11, 2019 | 6 years ago |
| RSI: Oversold | Sep 23, 2019 | 7 years ago |
| RSI: Oversold | Aug 19, 2019 | 7 years ago |
| SMA: Bearish | Jul 8, 2019 | 7 years ago |
| SMA: Bullish | Jul 1, 2019 | 7 years ago |
| SMA: Bearish | Apr 15, 2019 | 7 years ago |
| SMA: Bullish | Mar 25, 2019 | 7 years ago |
| SMA: Bearish | Jan 28, 2019 | 7 years ago |
| SMA: Bearish | Jan 21, 2019 | 7 years ago |
| SMA: Bullish | Dec 3, 2018 | 7 years ago |
| SMA: Bearish | Oct 1, 2018 | 8 years ago |
| SMA: Bullish | Aug 20, 2018 | 8 years ago |
Key statistics
- Market cap
- 7.25B
- Enterprise value
- 7.10B
- Trailing P/E
- 69.88
- Forward P/E
- 42.80
- PEG ratio
- 0.00
- Price / sales
- 7.66
- Price / book
- 10.19
- EPS (TTM)
- 1.32
- Beta
- 0.04
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 11.58%
- Revenue (TTM)
- 945.96M
- Revenue growth
- 58.10%
- Free cash flow
- 135.87M
- Total cash
- 568.76M
- Total debt
- 7.88M
- Return on equity
- 17.59%
- Shares outstanding
- 48.84M
- Short % of float
- 9.31%
- 50-day average
- 78.88
- 200-day average
- 59.94
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 103.63 +12.3% upside
Now 92.24
- Target (low)
- 87.00
- Target (mean)
- 103.63
- Target (high)
- 134.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy1
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate 0.39.
Financials — quick view
KNSA Revenue — quarterly 285.97M
KNSA Net income — quarterly 47.34M
KNSA EPS — quarterly 0.61
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 30, 2026 | 0.25 | — | — | — |
| Oct 27, 2026 | Sep 30, 2026 | 0.371 | 0.56 | +0.19 | +50.94% |
| Jul 28, 2026 | Jun 30, 2026 | 0.2995 | 0.30 | 0.00 | +0.17% |
| Apr 28, 2026 | Mar 31, 2026 | 0.18 | 0.27 | +0.09 | +50.00% |
| Feb 24, 2026 | Dec 31, 2025 | 0.29 | 0.17 | -0.12 | -41.38% |
| Oct 28, 2025 | Sep 30, 2025 | 0.33 | 0.23 | -0.10 | -30.30% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Goldman Sachs | main | Buy | Buy |
| Oct 28, 2026 | Wedbush | main | Outperform | Outperform |
| Oct 28, 2026 | Wells Fargo | main | Overweight | Overweight |
| Jul 30, 2026 | Goldman Sachs | main | Buy | Buy |
| Jul 29, 2026 | JP Morgan | main | Overweight | Overweight |
| Jul 29, 2026 | Canaccord Genuity | main | Buy | Buy |
About Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United Kingdom
- Website
- kiniksa.com
News
- JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122
- Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101
- Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $102
- Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110
- Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Crude Oil Moves Lower; Corning Earnings Top Views
- What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call
- Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript
- Pentair, JetBlue Airways, Hawkins And Other Big Stocks Moving Higher On Tuesday
Your note
Sign in to keep a note on KNSA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS L.P. | Unknown | Stock Award(Grant) | May 28, 2026 | 0 |
| BAKER BROTHERS LIFE SCIENCES, L.P. | Director | Stock Award(Grant) | Jun 2, 2025 | 0 |
| LEVY RICHARD S | Director | Conversion of Exercise of derivative security | Jul 30, 2026 | 22,359 |
| MALLEY THOMAS ROBERT | Director | Conversion of Exercise of derivative security | May 28, 2026 | 87,312 |
| MEGNA MICHAEL R | Officer | Sale | Sep 2, 2026 | 29,062 |
| MOAT ROSS | Chief Operating Officer | Conversion of Exercise of derivative security | Aug 31, 2026 | 16,307 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 17.30% | 6,971,361 | 643.04M | Jun 29, 2026 |
| Rubric Capital Management LP | 9.92% | 3,999,800 | 368.94M | Jun 29, 2026 |
| Baker Bros. Advisors, LP | 7.03% | 2,834,643 | 261.47M | Jun 29, 2026 |
| Blackrock Inc. | 6.80% | 2,739,615 | 252.70M | Jun 29, 2026 |
| Tang Capital Management, LLC | 5.61% | 2,259,889 | 208.45M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.74% | 1,911,335 | 176.30M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.27% | 1,318,452 | 121.61M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.93% | 1,180,466 | 108.89M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 2.41% | 970,000 | 89.47M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.37% | 954,719 | 88.06M | Jun 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 1.68% | 676,146 | 62.37M | Aug 30, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.58% | 637,600 | 58.81M | Aug 30, 2026 |